NASDAQ · KLTO
Healthcare · Biotechnology
$0.52
Down-$0.03 (-7.10%)
Updated Aug 19, 2026, 10:37 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
KLTO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning KLTO.
KLTO research
Company profile and research snapshot.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Mar 9, 2026
The rebranding and ticker change reflect the Company's strategic expansion into natural resources following the recently announced acquisition of Greenland Mines Corp. and control of the Skaergaard Project in
Benzinga · Mar 4, 2026
Benzinga · Mar 4, 2026
Klotho Neurosciences acquires Greenland Mines, gaining access to Skaergaard Project with an estimated $68 billion palladium and gold resource.
Benzinga · Mar 4, 2026
Post-closing, Klotho's CEO and CFO will remain in place. The Greenland Mines leadership team, led by CEO Bo Møller Stensgaard, will join the management team to operate the Greenland Mining division, and one new Board
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KLTO.
